Journal: Journal of Education, Health and Sport. 2025;79:58212. eISSN 2391-8306.
Authors: Daria Bednarczyk, Wiktoria Pysiewicz, Wiktor Garbarczyk, Agnieszka Napieralska, Albert Kapla, Michalina Jurkiewicz, Julia Bialeta, Katarzyrna Rowińska, Karolina Siembab and Alicja Çernohorská.
License and source: This article is licensed under the Creative Commons Attribution 4.0 International License (CC BY 4.0).
https://creativecommons.org/licenses/by/4.0/
Original publication available via the Journal of Education, Health and Sport
Summery: The following summary and key takeaways were prepared by the C4B team to support understanding of the scientific publication and are intended for informational purposes only. They do not replace the original article or professional medical advice.
Achondroplasia, caused by gain-of-function FGFR3 mutations, is the most common dwarfism (about 1 in 25,000). It produces disproportionate short stature and multiple health issues—orthopedic, neurological, respiratory, and hearing problems—requiring multidisciplinary care. Current management includes recombinant human growth hormone (modest, short-term height gains), surgical limb lengthening (Ilizarov, PRECICE, 4-segment methods) and spinal procedures for foramen magnum stenosis or kyphosis. Newer pharmacologic and molecular approaches show promise: C-type natriuretic peptide analogues (Vosoritide, TransCon CNP) stimulate endochondral growth; FGFR-targeting strategies include tyrosine kinase inhibitors (infigratinib), soluble decoy receptors (Recifercept), repurposed drugs (meclozine), and preclinical CRISPR/Cas9 gene editing. Ongoing trials aim to improve efficacy, safety, and long-term outcomes.
Key Take Aways:
This article will provide valuable insights into:
- Achondroplasia stems from FGFR3 overactivity and causes disproportionate short stature plus systemic complications.
- Traditional treatments (growth hormone, limb lengthening, spinal surgery) improve function but have limits and risks.
- Vosoritide and TransCon CNP directly target growth pathways and are promising clinical advances.
- Molecular therapies (recifercept, infigratinib, meclozine) are under study; safety and long-term data pending.
- CRISPR/Cas9 offers future potential to correct the root genetic defect but remains preclinical.